Table 2

Replication cohort and meta-analysis results for replicated loci for proliferative lupus nephritis and end-stage renal disease in SLE

Discovery cohort (Sweden)Replication cohort (multiethnic)**Meta-analysis††
LocusSNVMAFMAFP valueOR (95% CI)MAFMAFP valueOR (95% CI)P valueORI2 %
Proliferative LN vs SLE-non-LNpLN+
n=153
LN-
n=620
pLN+
n=93
LN-
n=623
APOA1BPrs9429600.080.032.76E-053.23 (1.87 to 5.59)0.080.050.0371.99 (1.04 to 3.8)1.16E-052.640
APOA1BPrs9429610.080.032.76E-053.23 (1.87 to 5.59)0.080.050.0371.99 (1.04 to 3.8)1.16E-052.640
PRDM1rs19842240.250.386.14E-050.54 (0.4 to 0.73)0.250.310.0360.66 (0.44 to 0.97)2.50E-050.580
PRDM1rs69245350.260.385.08E-050.53 (0.39 to 0.72)0.250.300.0290.65 (0.44 to 0.96)1.58E-050.590
PRDM1rs5357800.260.387.88E-050.54 (0.4 to 0.73)0.300.340.0190.63 (0.43 to 0.93)3.19E-030.5930
ESRD vs SLE non-LNESRD+
n=35
LN-
n=620
ESRD+
n=73
LN-
n=623
MERTKrs728256390.130.027.84E-067.58 (3.12 to 18.43)0.050.030.0442.57 (1.02 to 6.46)8.95E-075.500
MERTKrs560979100.130.029.52E-067.32 (3.03 to 17.68)0.050.030.0432.59 (1.03 to 6.5)1.03E-065.400
MERTKrs728256500.130.029.49E-067.33 (3.03 to 17.68)0.050.030.0432.59 (1.03 to 6.5)1.03E-065.400
  • *Multiethnic cohort, all ethnicities combined.

  • †Each replication population analysed separately by logistic regression, then included in a meta-analysis with the discovery cohort.

  • ESRD, end-stage renal disease; I2, I2-statistics for heterogeneity of studies; LN, lupus nephritis; MAF, minor allele frequency; pLN, proliferative LN.